CLOs on the Move

Adheris

www.adheris.com

 
Adheris is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

FLAVORx, Inc.

FLAVORx, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Bethesda, MD. To find more information about FLAVORx, Inc., please visit www.flavorx.com

Henry County Medical Center

Located in Paris, TN, Henry County Medical Center is a progressive, integrated healthcare organization committed to serving the healthcare needs of Henry County and the adjoining region. Including a 142-bed hospital and other facilities, the medical center provides a variety of outpatient services, as well as inpatient care. Additionally, HCMC owns and operates 8 provider clinics in various specialties. Henry County Medical Center is a county-owned and operated nonprofit institution.

EandM Devices

E&M Devices Inc. is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cunningham Drug Co Inc

Cunningham Drug Co Inc is a New Tazewell, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.